Caplacizumab Completed Phase 3 Trials for Acquired Thrombotic Thrombocytopenic Purpura Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02553317Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura